BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9679456)

  • 1. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
    Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
    Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
    Chan AL; Juarez M; Allen R; Volz W; Albertson T
    Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
    Gomer CJ; Ferrario A
    Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
    Ferrario A; Kessel D; Gomer CJ
    Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
    McMahon KS; Wieman TJ; Moore PH; Fingar VH
    Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
    Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
    Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
    Taber SW; Fingar VH; Coots CT; Wieman TJ
    Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
    Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
    Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
    Wong Kee Song LM; Wang KK; Zinsmeister AR
    Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
    Ohtani K; Usuda J; Ichinose S; Ishizumi T; Hirata T; Inoue T; Maehara S; Imai K; Kubota M; Tsunoda Y; Yamada M; Tsutsui H; Yamada K; Kuroiwa Y; Furukawa K; Okunaka T; Kato H
    Int J Oncol; 2008 Feb; 32(2):397-403. PubMed ID: 18202762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
    Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
    Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dynamics of photosensitizer in the cell].
    Aizawa K; Kuroiwa Y; Tsuchida T; Xiahedin I; Shibuya H; Saito K
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):22-6. PubMed ID: 8546464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP activation by photodynamic therapy increases treatment induced photosensitization.
    Wong S; Luna M; Ferrario A; Gomer CJ
    Lasers Surg Med; 2004; 35(5):336-41. PubMed ID: 15611953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
    Wong TW; Aizawa K; Sheyhedin I; Wushur C; Kato H
    J Pharmacol Sci; 2003 Oct; 93(2):136-42. PubMed ID: 14578580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of photodynamic therapy-induced early apoptosis in human salivary gland tumor cells in vitro and in a mouse tumor model.
    Kaneko T; Chiba H; Yasuda T; Kusama K
    Oral Oncol; 2004 Sep; 40(8):787-92. PubMed ID: 15288832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP.
    Tsai SR; Yin R; Huang YY; Sheu BC; Lee SC; Hamblin MR
    Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):123-30. PubMed ID: 25462575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6.
    Katsumi TA; Aizawa K; Kuroiwa Y; Saito K; Kurata Y; Ii Y; Okunaka T; Konaka C; Kato H
    Photochem Photobiol; 1996 Oct; 64(4):671-5. PubMed ID: 8863472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines.
    Nakamura H; Suzuki Y; Takeichi M; Saito T; Takayama M; Aizawa K
    Int J Gynecol Cancer; 2002; 12(2):177-86. PubMed ID: 11975677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents.
    Caruso JA; Mathieu PA; Joiakim A; Leeson B; Kessel D; Sloane BF; Reiners JJ
    Mol Pharmacol; 2004 Apr; 65(4):1016-28. PubMed ID: 15044632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.